Valuation as at 2026-08-14 · see also the ASX 300 Most Undervalued screen
About ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software.
Source: Yahoo Finance company profile · factual description, not KashVector commentary
ResMed Inc. RMD.AX
Healthcare · Medical Instruments & Supplies
ResMed Inc.'s price & financial trends
Each card is labelled with its own reporting period — quarterly where Yahoo provides it for this market, annual otherwise.
Data as at 2026-08-14
Share price · last 2 years
Earnings per share (diluted) Per quarter
Free cash flow Per quarter
Dividend per share Per quarter
Value investing scale · Buffett · Dalio · Graham
Intrinsic value estimate · 5-year forecast
Assumptions used in this valuation
Every input below is either fetched live from Yahoo Finance or a documented default — nothing is hidden.
| Bear | Base | Bull | |
|---|---|---|---|
| 5-yr FCF growth | 2.7% | 5.4% | 8.1% |
| Terminal growth | 2.5% | 2.5% | 2.5% |
| WACC (discount rate) | 10.16% | 9.16% | 8.16% |
Cost of Equity = Risk-free rate + Beta × Equity Risk Premium = 4.80% + 0.75 × 6.00% = 9.29% · WACC = weighted by 98%/2% capital structure
These numbers come from running ResMed Inc.'s cash flows through the mechanical DCF formula and assumptions above — not from any view on the news, management, or RMD.AX's competitive position. What is DCF?
Want to test your own growth or discount-rate assumptions?Open the full interactive calculator, pre-filled with RMD.AX →
More ASX stocks we've valued
Not financial advice. DCF valuations are highly sensitive to assumptions — small changes in growth rate or discount rate produce large swings in output. This is a mechanical calculation, not a recommendation to buy, hold, or sell.
About this valuation
Computed on 2026-08-14 from Yahoo Finance data, using the same engine as the full DCF tool and the ASX 300 Most Undervalued screen. Every figure above is a point-in-time snapshot of that date — change any assumption yourself in the interactive tool for a live one.
Frequently asked questions
Is ResMed Inc. (RMD.AX) undervalued?
The Base-case DCF estimates intrinsic value at $16.35 vs a price of $32.02 on 2026-08-14 — a -48.9% margin, so the Base case reads overvalued. This is a mechanical output, not advice.